Assembly Bioscie SEC Filings

Assembly Biosciences, Inc. reported a Q1 2026 net loss of $9.1M, slightly higher than the $8.8M loss a year earlier, as it continued investing in antiviral R&D. Collaboration revenue from Gilead was $8.2M, down from $9.4M, reflecting the timing of research services.

Total operating expenses were $19.6M, with research and development of $14.9M and general and administrative costs of $4.7M. Interest and other income rose to $2.3M due to a larger securities portfolio.

Cash, cash equivalents and marketable securities totaled $226.6M as of March 31, 2026, and management states this should fund operations into 2028. The company’s pipeline includes partnered genital herpes helicase‑primase inhibitors, HDV entry inhibitor ABI‑6250, capsid assembly modulator ABI‑4334 (now seeking partners) and NNPI candidate ABI‑7272.

Assembly Biosciences, Inc. reported first quarter 2026 results that show continued R&D investment alongside a manageable loss and solid cash position. Cash, cash equivalents and marketable securities totaled $226.6 million as of March 31, 2026, which the company believes can fund operations into 2028.

For the quarter, collaboration revenue from its Gilead partnership was $8.2 million, while research and development expenses were $14.9 million and general and administrative expenses were $4.7 million. Net loss attributable to common stockholders was $9.1 million, or $0.54 per share.

Operationally, the company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 and chronic toxicology studies for ABI-6250 in hepatitis delta virus. A Phase 2 study for ABI-6250 is expected to begin in the fourth quarter of 2026, and a decision on opting into a 40% U.S. cost-profit share with Gilead for the herpes program is planned by mid-2026.

Assembly Biosciences is asking stockholders to approve five key items at its 2026 annual meeting. The virtual-only meeting is scheduled for June 4, 2026 at 8:00 a.m. PDT. Holders of 15,892,608 shares of common stock as of April 10, 2026 may vote.

Stockholders will vote on electing nine directors, an advisory “say on pay” for named executive officers, and ratifying Ernst & Young LLP as auditor for 2026. They are also asked to approve increasing the 2018 Stock Incentive Plan share reserve by 1,200,000 shares and raising the Employee Stock Purchase Plan reserve to 515,000 shares. The Board recommends voting “FOR” all proposals and highlights a mainly independent Board, annual director elections, proxy access and the absence of a poison pill.

Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist reported a mix of equity grants and related share sales. She received a grant of 6,500 restricted stock units (RSUs), scheduled to vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming continuous service. Footnotes state that RSUs represent 65% of her annual equity grant and that the remaining 35% of RSUs is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. On March 30, 2026, she sold a total of 328 common shares in open-market transactions at weighted average prices of $26.6502 and $27.49 per share to cover tax withholding obligations under a mandatory sell-to-cover rule, described as a non-discretionary transaction. Following these transactions, she directly holds 11,089 common shares.

Assembly Biosciences Chief Manufacturing Officer Nicole S. White received a grant of 26,000 restricted stock units (RSUs) and completed a small mandated share sale to cover taxes. The RSUs vest in four equal installments on March 29 of each year from 2027 through 2030, subject to continuous service. Footnotes state that 35% of the RSUs are contingent on stockholder approval of an amendment to increase shares authorized under the company’s 2018 Stock Incentive Plan. To satisfy tax withholding from RSU vesting, White sold a total of 197 common shares in open-market “sell-to-cover” transactions, described as required by a Compensation Committee administrative rule rather than discretionary trading. Following these transactions, she directly holds 37,477 common shares.

Assembly Biosciences Chief Medical Officer Anuj Gaggar received an equity grant tied to company stock. The Form 4 reports a grant of 26,000 shares underlying restricted stock units that were awarded at no cash cost to him.

The RSUs vest in four equal installments on March 29 of 2027, 2028, 2029 and 2030, assuming he remains in continuous service. The award represents 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an increase in shares authorized under the company’s 2018 stock incentive plan. After this grant, he directly holds 28,000 shares, including 2,000 shares previously acquired through the employee stock purchase plan.

Assembly Biosciences granted Chief Scientific Officer William E. Delaney IV 26,000 restricted stock units (RSUs) on March 29, 2026. The RSUs vest in four equal annual installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service on each date.

The RSUs represent 65% of his annual equity grant, while the remaining 35% is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. After this grant, Delaney directly holds 45,642 common shares, including 2,909 shares acquired through the employee stock purchase plan on May 14, 2025.

Assembly Biosciences CEO and President Jason A. Okazaki received a grant of 94,250 restricted stock units (RSUs) of common stock. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming continuous service on each vesting date. The RSUs represent 65% of his annual equity grant, while the remaining 35% of RSUs are contingent on stockholder approval of an amendment to the company’s Amended and Restated 2018 Stock Incentive Plan to increase shares authorized under the plan. Following this award, Okazaki beneficially owns 111,916 shares, including 2,909 shares previously acquired under the company’s Employee Stock Purchase Plan.